Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is a Beat in Store for Abbott (ABT) This Earnings Season?

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.

    Zacks Equity Research

    QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

    by Zacks Equity Research

    QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

      Zacks Equity Research

      QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm

      by Zacks Equity Research

      QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.

        Zacks Equity Research

        Abbott-North West London Pathology Expand in Diagnostics

        by Zacks Equity Research

        Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.

          Zacks Equity Research

          QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View

          by Zacks Equity Research

          QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.

            Zacks Equity Research

            QIAGEN Strengthens Cancer Research Foothold on New License

            by Zacks Equity Research

            QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.

              Zacks Equity Research

              Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo

              by Zacks Equity Research

              Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.

                Zacks Equity Research

                QIAGEN & Bristol-Myers Squibb Partner on Cancer Research

                by Zacks Equity Research

                QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.

                  Zacks Equity Research

                  Qiagen Banks on Molecular Diagnostic amid Currency Woes

                  by Zacks Equity Research

                  On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).

                    Zacks Equity Research

                    QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View

                    by Zacks Equity Research

                    QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.